Preliminary report on cardiovascular responses to urapidil during intubation and extubation.
Urapidil (Ebrantil), a new antihypertensive agent with central and peripheral sites of action, has proven effective in the management of both chronic and acute hypertension. This study investigates its effects on cardiovascular responses during intubation and extubation under general anesthesia. Thirty normotensive patients (ASA I-II) were randomized into control (I, without urapidil, n = 10); lower dose (II, 0.4 mg/kg, n = 10); and higher dose (III, 0.6 mg/kg, n = 10) groups. A significant fall of blood pressure was observed in all patients within 1 min after urapidil administration (P < 0.05), and the magnitude of the decrease was related to blood pressure before treatment. However, no transient drop of blood pressure to hypotensive values was observed. The results suggest that urapidil could be used under general anesthesia in patients to control fluctuating blood pressure during intubation and extubation. The increased heart rate (P < 0.05) seen for several minutes after urapidil administration may have been due to the patients' hypovolemic state.
Ye
T
T
Department of Anesthesiology, PUMC Hospital, CAMS, Beijing.
Luo
A
A
Ren
H
H
Xu
J
J
Gao
M
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000768:Anesthesia, General; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects*; D005260:Female; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D007440:Intubation; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology*
D000959:Antihypertensive Agents; D010879:Piperazines; C015568:urapidil